Pfizer (PFE)
(Delayed Data from NYSE)
$28.64 USD
-0.28 (-0.97%)
Updated May 17, 2024 04:01 PM ET
After-Market: $28.67 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PFE 28.64 -0.28(-0.97%)
Will PFE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
The Zacks Analyst Blog Highlights Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet
Top Stock Reports for Amazon.com, Visa & Pfizer
Other News for PFE
Moderna vaccine patent upheld by European Patent Office: report
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Pfizer Stock: Rebound Has Started (Technical Analysis)
Moderna wins European patent case in Pfizer, BioNTech dispute, FT reports
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale